Board of Directors
Born: 1959. Title: Member of the Board since 2016 and Chairman of the Remuneration Committee.
Education: Has studied industrial economics at Linköping University’s Institute of Technology.
Background: CEO of Vitrolife AB since 2011. Former CEO of the publically traded companies Stille AB and Artema AB as well as of a number of unlisted medical technology companies. Former Chairman of the Boards of SBL Vaccin AB, Neoventa Medical AB, Airsonett AB and other companies, primarily in the life science sector. Former Business Unit Director at Baxter.
Other directorships: No other directorships.
Shares in Medivir: 1,605 class B shares.
Anna Malm Bernsten
Born: 1961. Title: Chairman of the Board. Member of the Board since 2006. Member of the Audit Committee and the R&D Committee.
Education: M.Sc. in Engineering.
Background: M.Sc. in Engineering with an extensive knowledge of the life sciences sector. Runs own consultancy firm operating in the fields of leadership strategy and business development. Experience of senior positions with, amongst others, GE Healthcare Life Sciences, Pharmacia, Assa Abloy, Medivir and Baxter Medical. Former President & CEO of Carmeda AB.
Other directorships: Chairman of the Boards of CEBA AB and Oatly AB. Member of the Boards of Arcam, Cellavision, Neurovive, Pågengruppen and Björn Axén. Former Member of the Board of BioPhausia AB.
Shares in Medivir: 1,224 class B shares.
Born: 1954. Title: Member of the Board since 2014. Member of the R&D Committee and the Audit Committee.
Education: Doctor of Medicine and Associate Professor in physiology at the Karolinska Institute.
Background: Physician (specialising in anaesthesia and intensive care), dentist.
Other directorships: Chairman of the Boards of the Karolinska University Hospital and TFS International AB, Member of the Boards of the Swedish Research Council, SwedenBio, AnaMar AB, Infant Bacterial Therapeutics AB, Mereo Biopharma Ltd, RSPR Pharma AB, and Viscogel AB, and a senior advisor to Phase4 Partners, UK.
Shares in Medivir: 1,345 class B shares.
Anders R Hallberg
Born: 1945. Title: Member of the Board since 2012. Chairman of the R&D Committee.
Education: Professor of Medicinal Chemistry at Uppsala University’s Faculty of Pharmacy.
Background: Held a number of positions as a scientific advisor at Astra Zeneca and smaller pharmaceutical companies between 1990 and 2006. Prior to this, he was the Head of the Medicinal Chemistry Department at Astra in Lund. Vice-Chancellor of Uppsala University between 2006 and 2011. He has published over 270 scientific articles, a large number of which are on the subject of pharmaceuticals for the treatment of infectious diseases, and co-inventor of a large number of granted patents. Member of the Royal Swedish Academy of Sciences, and the Royal Swedish Academy of Engineering Sciences. Awarded honorary doctorates in Sweden and other countries.
Other directorships: Member of the Boards of foundations and universities.
Shares in Medivir: 1,030 class B shares.
Born: 1954. Title: Member of the Board since 2015. Member of the R&D Committee.
Education: Physician, Doctor of Medicine and Associate Professor in Virology at the Karolinska Institute. Scientific studies at MIT in Cambridge, USA.
Background: Previously worked as a researcher, Medical Director and Research Director at, amongst others, Roche, Astra, Pharmacia & Upjohn, Medivir and Algeta ASA. Former CEO of Axelar AB, Akinion AB and OncoReg AB and a former Member of the Board of Light-up AB and Oxypharma AB. He has published over 100 scientific articles and abstracts, the majority of which have been on the subject of pharmaceuticals and pharmaceutical development for the treatment of cancer and infectious diseases. He also runs a small real estate business. He is currently the Chief Medical Officer of Glionova AB and Oncopeptides AB.
Other directorships: Member of the Boards of small, wholly-owned real estate companies.
Shares in Medivir: 2,250 class B shares.
Born: 1957. Title: Member of the Board since 2015. Member of the Remuneration Committee and Chairman of the Audit Committee.
Education: B.Sc. in Economics and Business Administration from the Stockholm School of Economics.
Background: Extensive experience of the financial and equity markets and of corporate governance issues. Previous employed by Neonet, Odin Förvaltning, Nordea Asset Management and SEB Asset Management, amongst others.
Other directorships: Founder and now Chairman of the Board of Nordic Investor Services AB. Member of the Boards of Concordia Maritime AB, Hans Andersson Recycling AB, NeuroVive Pharmaceutical AB, Collector AB and Stampen AB.
Shares in Medivir, including family: 5,250 class B shares.
Born: 1979. Title: Member of the Board, appointed by the Unionen trade union, since 2013.
Background: Ph.D. in Chemistry from KTH Royal Institute of Technology. Employed in 2008 as a Senior Research Scientist and team leader in the Chemistry Department.
Shares in Medivir: 1,338 class B shares.